TTR and cutaneous mastocytosis: Until the recent approval of tafamidis, a TTR stabiliser, there were no specific treatment options for those with isolated ATTR-CM and the mortality rate of patients with the diagnosis of ATTR-CM was mentioned to be up to 64% after 5 years (Connors et al., Circulation 2016; 133(3):282–290).